SCHEMBL9969436

SCHEMBL9969436

C[C@H](CC(C)(C)C)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.51
KDM4E B2RXH2 3/20 0.51
KCNJ1 P48048 1/20 0.47
KCNH2 Q12809 1/20 0.47
MAPT P10636 6/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
PHLPP2 Q6ZVD8 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HPGD P15428 1/20 0.44
HSD17B10 Q99714 2/20 0.44
ACHE P22303 1/20 0.44
NPC1 O15118 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16788783 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EKCNJ1KCNH2MAPT
SCHEMBL12939649 1.00 ALDH1A1 (0.51) ALDH1A1KDM4EKCNJ1KCNH2MAPT
SCHEMBL18177878 0.81 ALDH1A1 (0.62) ALDH1A1KDM4EMAPTL3MBTL1CYP1A2
SCHEMBL13638756 0.81 ALDH1A1 (0.50) ALDH1A1KDM4EMAPTL3MBTL1CYP1A2
SCHEMBL5918492 0.80 RIPK1 (0.46) ACHE
SCHEMBL16806060 0.79 ALDH1A1 (0.50) ALDH1A1KDM4EKCNJ1KCNH2MAPT
SCHEMBL173199 0.79 ALDH1A1 (0.50) ALDH1A1KDM4EKCNJ1KCNH2MAPT
SCHEMBL16806066 0.79 ALDH1A1 (0.50) ALDH1A1KDM4EKCNJ1KCNH2MAPT
SCHEMBL9805956 0.78 KCNJ1 (0.49) ALDH1A1KDM4EKCNJ1KCNH2MAPT
SCHEMBL6554242 0.78 ALDH1A1 (0.53) ALDH1A1KDM4EKCNJ1KCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202843-B2 Macrocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. (US) 2012-06-19 US disclosed
US-8202843-B2 Macrocyclic compounds and methods of making and using the same RIB-X PHARMACEUTICALS, INC. (US) 2012-06-19 US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 US disclosed
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same VIP, PROKR1, PGC ALDH1A1 3986/4885KDM4E 4582/4885KCNJ1 3635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.